SEC Tracker
Get the app

Spero Therapeutics SPRO

Spero Therapeutics CEO to retire

Item 5.02 Executive or director change

Form
8-K
Filed
Importance
Major
  1. Timothy Keutzer to retire Dec 31, 2026
  2. Consulting agreement expected for advisory services until Feb 28, 2027
  3. 11 years of service with the company

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Spero Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Lineage Cell Therapeutics LCTX public float $162M, Jun 30, 2025
  2. Forte Biosciences FBRX public float $157M, Jun 30, 2025
  3. Monopar Therapeutics MNPR public float $156M, Jun 30, 2025
  4. 4D Molecular Therapeutics FDMT public float $166M, Jun 30, 2025
  5. XOMA Royalty XOMA public float $168M, Jun 30, 2025